Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

v3.10.0.1
Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Disaggregation of Revenue
The following table presents net revenues disaggregated by type:

 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2018
 
2017
 
2018
 
2017
Prescribed dietary supplements
 
$1,925,543

$


$3,669,791

$

Prescription drugs
 
2,785,376




5,301,247



Sales force revenue
 
74,219



 
296,875



Grant revenue
 


157,800

 


542,006

Total revenue
 
$4,785,138

$157,800

$9,267,913

$542,006